Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers
In this study, we clarified that the cBAF subcomplex is deficient in the SWI/SNF complex, resulting in dependency on the CBP/p300 paralog pair. Simultaneous inhibitors of the CBP/p300 paralog pair show promise for cBAF-deficient lung cancer, as well as rare cancers such as malignant rhabdoid tumors, epithelioid sarcomas, and synovial sarcomas.
Authors
- Hideaki Ogiwara (ORCID: https://orcid.org/0000-0003-0860-1807)
- Hiroshi Yoshida (ORCID: https://orcid.org/0000-0002-7569-7813)
- Takafumi Shimizu
- Daiki Kato
- Mariko Sasaki
Institutions
- Sumitomo Chemical (Japan) (JP)
- Sumitomo Dainippon Pharma (Japan) (JP)
- National Cancer Centre Japan (JP)
- National Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
- National Cancer Research Institute (GB)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0484
- Citations
- 1
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.23
Funders
- Japan Agency for Medical Research and Development
- Japan Foundation for Pediatric Research
- Lastentautien Tutkimussäätiö
- Daiichi Sankyo Foundation of Life Science
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science
- Daiichi Sankyo Europe